Michael Jandernoa - Perrigo Company Independent Director

<div class='circular--portrait' style='background:#000000;color: #f2f2f2;font-size:4em;padding-top: 25px;;'>PC</div>
PRGO -- USA Stock  

Last Earning Announcement: 31st of December 2015  

  Director
Mr. Michael J. Jandernoa is an Independent Director of the Company. He served as Perrigos Chief Executive Officer from 1988 to 2000 and as Chairman of the Board from 1991 to 2003. Mr. Jandernoa also previously served in various other executive capacities with Perrigo since 1979. He is a general partner of 42North Partners was a director of Fifth Third Bank West Michigan, a Michigan banking corporation, from 2004 to December 2009 and a director of Steelcase, Inc., a manufacturer of casegood products and furniture systems for the office furniture industry, from 2002 to March 2010. Mr. Jandernoa served on the Board of the Strategic Economic Investment and Commercial Board through early 2011. He currently serves as First Vice Chair of the Business Leaders of Michigan, Inc. Mr. Jandernoa also serves on several private company and nonprofit boards.
Age: 64  Director Since 2007      
353 1 709 4000  http://www.perrigo.com

Michael Jandernoa Latest Insider Activity

Perrigo Company Management Efficiency

Perrigo Company has return on total asset (ROA) of 2.63 % which means that it generated profit of $2.63 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of 3.28 %, meaning that it created $3.28 on every $100 dollars invested by stockholders. Perrigo Company management efficiency ratios could be used to measure of how well the company is managing its routine affairs as well as how well it utilizes its assets and manages liabilities.
The company currently holds 3.6 B in liabilities with Debt to Equity (D/E) ratio of 0.62, which is about average as compared to similar companies. Perrigo Company has a current ratio of 1.82, which is within standard range for the sector.

Similar Executives

Showing few of many executives

DIRECTOR Since

Christopher BodineAllergan Plc
2013
Joseph EchevarriaPfizer Inc
2015
J MoreauDr Reddys Laboratories
2007
Shantanu NarayenPfizer Inc
2019
Louise ParentZoetis Inc
2013
Frank DAmelioZoetis Inc
2016
Kalpana MorpariaDr Reddys Laboratories
2007
Arthur RyanRegeneron Pharmaceuticals
2003
Anupam PuriDr Reddys Laboratories
2002
Christine PoonRegeneron Pharmaceuticals
2010
Alfred GilmanRegeneron Pharmaceuticals
1990
Christopher CoughlinAllergan Plc
2016
Hans HaslerDr Reddys Laboratories
2016
Patrick OSullivanAllergan Plc
2013
Helen HobbsPfizer Inc
2011
Michael GallagherAllergan Plc
2015
Ashok GangulyDr Reddys Laboratories
2009
William SteereZoetis Inc
2013
Nesli BasgozAllergan Plc
2014
Sanjay KhoslaZoetis Inc
2013
Anthony ColesRegeneron Pharmaceuticals
2017

Company Summary

Perrigo Company plc manufactures and supplies over-the-counter health and wellness solutions in the United States, Europe, and internationally. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland. Perrigo Company operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on BATS Exchange. It employs 11000 people.Perrigo Company Plc (PRGO) is traded on BATS Exchange in USA and employs 11,000 people.

Perrigo Company Leadership Team

John Hendrickson, President
Gary Cohen, Independent Director
Arthur Shannon, IR Contact Officer
Ronald Winowiecki, Acting CFO
Svend Andersen, Executive Vice President and President - Consumer Healthcare International
Judy Brown, CFO and Executive VP
Laurie Brlas, Independent Director
Donal OConnor, Independent Director
James Michaud, Chief Human Resource Officer, Executive Vice President
Louis Yu, Executive Vice President - Global Quality
John Wesolowski, Executive Vice President and Presidentident - RX
Theodore Samuelsto, Independent Director
Scott Jamison, Executive Vice President General Manager - Nutritionals
Ellen Hoffing, Independent Director
Marc Coucke, Executive Vice President General Manager - Omega Pharma Business
Adriana Karaboutis, Independent Director
Michael Jandernoa, Independent Director
Paul Weninger, Executive Vice President - Global Quality Operations
Thomas Farrington, Senior Vice President CIO
Herman Morris, Independent Director
Jeffrey Needham, Executive Vice President General Manager - Consumer Healthcare
Todd Kingma, Executive VP, General Counsel and Secretary
Rolf Classon, Independent Director
Raymond Silcock, CFO
Shlomo Yanai, Independent Director Nominee
Jatin Shah, Senior Vice President Chief Scientific Officer
Michael Stewart, Senior Vice President - Global Human Resources
Jeffrey Kindler, Independent Director
Jacqualyn Fouse, Independent Director
Grainne Quinn, Executive Vice President Chief Medical Officer
Theodore Samuels, Independent Director
Geoffrey Parker, Independent Director
Murray Kessler, President CEO, Director
Sharon Kochan, Executive VP and General Manager of International
Gary Kunkle, Lead Independent Director
Joseph Papa, Chairman and CEO
Marry Brlas, Independent Chairman of the Board
Bradley Alford, Independent Director
Jeffrey Smith, Independent Director
Bradley Joseph, IR Contact Officer
James Dillard, Executive Vice President Chief Scientific Officer
Douglas Boothe, Executive Vice President General Manager - Rx Pharmaceuticals
Ronald Janish, Executive Vice President - Global Operations and Supply Chain
Uwe Rohrhoff, President CEO, Director

Stock Performance Indicators

Did you try this?

Run Global Markets Map Now

   

Global Markets Map

Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
All  Next Launch Module

Currently Active Assets on Macroaxis

S   
Sold over 300 shares of
six days ago
Traded for 8.62
GM   
Sold over 100 shares of
six days ago
Traded for 25.24
XOM   
Sold over 60 shares of
six days ago
Traded for 44.08
OTPBF   
Sold over 100 shares of
six days ago
Traded for 28.82
MSFT   
Sold few shares of
six days ago
Traded for 206.26
Please check Your Equity Center. Please also try Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page